vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and SANDRIDGE ENERGY INC (SD). Click either name above to swap in a different company.
SANDRIDGE ENERGY INC is the larger business by last-quarter revenue ($39.4M vs $21.9M, roughly 1.8× Cue Biopharma, Inc.). SANDRIDGE ENERGY INC runs the higher net margin — 54.9% vs 7.2%, a 47.7% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 1.1%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 14.1%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
SandRidge Energy, Inc. is a company engaged in hydrocarbon exploration in the Mid-Continent region of the United States. It is organized in Delaware and headquartered in Oklahoma City, Oklahoma.
CUE vs SD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $39.4M |
| Net Profit | $1.6M | $21.6M |
| Gross Margin | — | — |
| Operating Margin | 9.0% | 38.5% |
| Net Margin | 7.2% | 54.9% |
| Revenue YoY | 1292.3% | 1.1% |
| Net Profit YoY | 116.7% | 23.1% |
| EPS (diluted) | $0.05 | $0.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $39.4M | ||
| Q3 25 | $2.1M | $39.8M | ||
| Q2 25 | $3.0M | $34.5M | ||
| Q1 25 | $421.0K | $42.6M | ||
| Q4 24 | $1.6M | $39.0M | ||
| Q3 24 | $3.3M | $30.1M | ||
| Q2 24 | $2.7M | $26.0M | ||
| Q1 24 | $1.7M | $30.3M |
| Q4 25 | $1.6M | $21.6M | ||
| Q3 25 | $-7.4M | $16.0M | ||
| Q2 25 | $-8.5M | $19.6M | ||
| Q1 25 | $-12.3M | $13.0M | ||
| Q4 24 | — | $17.6M | ||
| Q3 24 | $-8.7M | $25.5M | ||
| Q2 24 | $-10.2M | $8.8M | ||
| Q1 24 | $-12.3M | $11.1M |
| Q4 25 | 9.0% | 38.5% | ||
| Q3 25 | -353.4% | 37.8% | ||
| Q2 25 | -292.3% | 53.7% | ||
| Q1 25 | -2921.4% | 28.6% | ||
| Q4 24 | — | 25.9% | ||
| Q3 24 | -264.2% | 28.3% | ||
| Q2 24 | -390.6% | 23.9% | ||
| Q1 24 | -737.8% | 27.8% |
| Q4 25 | 7.2% | 54.9% | ||
| Q3 25 | -346.6% | 40.1% | ||
| Q2 25 | -287.1% | 56.6% | ||
| Q1 25 | -2911.4% | 30.6% | ||
| Q4 24 | — | 45.1% | ||
| Q3 24 | -259.6% | 84.8% | ||
| Q2 24 | -382.7% | 33.9% | ||
| Q1 24 | -719.1% | 36.7% |
| Q4 25 | $0.05 | $0.59 | ||
| Q3 25 | $-0.07 | $0.43 | ||
| Q2 25 | $-0.09 | $0.53 | ||
| Q1 25 | $-0.17 | $0.35 | ||
| Q4 24 | — | $0.46 | ||
| Q3 24 | $-0.17 | $0.69 | ||
| Q2 24 | $-0.20 | $0.24 | ||
| Q1 24 | $-0.25 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $111.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.4M | $510.9M |
| Total Assets | $42.2M | $644.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $111.0M | ||
| Q3 25 | $11.7M | $101.2M | ||
| Q2 25 | $27.5M | $102.8M | ||
| Q1 25 | $13.1M | $99.7M | ||
| Q4 24 | $22.5M | $98.1M | ||
| Q3 24 | $32.4M | $92.7M | ||
| Q2 24 | $30.0M | $209.9M | ||
| Q1 24 | $41.0M | $207.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | $26.4M | $510.9M | ||
| Q3 25 | $13.2M | $492.4M | ||
| Q2 25 | $18.2M | $480.2M | ||
| Q1 25 | $6.6M | $464.9M | ||
| Q4 24 | $17.5M | $460.5M | ||
| Q3 24 | $25.4M | $446.8M | ||
| Q2 24 | $21.6M | $424.8M | ||
| Q1 24 | $30.0M | $419.7M |
| Q4 25 | $42.2M | $644.0M | ||
| Q3 25 | $31.6M | $619.0M | ||
| Q2 25 | $40.7M | $602.3M | ||
| Q1 25 | $22.3M | $588.3M | ||
| Q4 24 | $32.2M | $581.5M | ||
| Q3 24 | $44.8M | $565.2M | ||
| Q2 24 | $42.3M | $529.6M | ||
| Q1 24 | $54.0M | $527.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $31.7M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 36.6% |
| Capex IntensityCapex / Revenue | 0.0% | 43.8% |
| Cash ConversionOCF / Net Profit | -0.68× | 1.46× |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $31.7M | ||
| Q3 25 | $-9.0M | $25.3M | ||
| Q2 25 | $-3.4M | $22.9M | ||
| Q1 25 | $-8.2M | $20.3M | ||
| Q4 24 | $-36.3M | $26.0M | ||
| Q3 24 | $-7.5M | $20.8M | ||
| Q2 24 | $-10.0M | $11.4M | ||
| Q1 24 | $-9.8M | $15.7M |
| Q4 25 | — | $14.4M | ||
| Q3 25 | — | $5.9M | ||
| Q2 25 | $-3.4M | $7.3M | ||
| Q1 25 | $-8.3M | $13.9M | ||
| Q4 24 | $-36.4M | $13.2M | ||
| Q3 24 | $-7.5M | $10.8M | ||
| Q2 24 | $-10.0M | $9.0M | ||
| Q1 24 | $-9.8M | $14.6M |
| Q4 25 | — | 36.6% | ||
| Q3 25 | — | 14.9% | ||
| Q2 25 | -116.5% | 21.0% | ||
| Q1 25 | -1976.7% | 32.7% | ||
| Q4 24 | -2309.3% | 33.8% | ||
| Q3 24 | -225.7% | 36.1% | ||
| Q2 24 | -376.2% | 34.5% | ||
| Q1 24 | -573.0% | 48.1% |
| Q4 25 | 0.0% | 43.8% | ||
| Q3 25 | 0.0% | 48.6% | ||
| Q2 25 | 0.9% | 45.2% | ||
| Q1 25 | 35.6% | 15.0% | ||
| Q4 24 | 4.2% | 32.9% | ||
| Q3 24 | 0.0% | 33.3% | ||
| Q2 24 | 0.4% | 9.4% | ||
| Q1 24 | 3.2% | 3.7% |
| Q4 25 | -0.68× | 1.46× | ||
| Q3 25 | — | 1.58× | ||
| Q2 25 | — | 1.17× | ||
| Q1 25 | — | 1.56× | ||
| Q4 24 | — | 1.48× | ||
| Q3 24 | — | 0.82× | ||
| Q2 24 | — | 1.30× | ||
| Q1 24 | — | 1.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
SD
| Oil Reserves | $19.0M | 48% |
| Natural Gas Reserves | $11.6M | 30% |
| Natural Gas Liquids Reserves | $8.7M | 22% |
